Research programme: monoclonal antibody therapeutics - Arsanis Biosciences

Drug Profile

Research programme: monoclonal antibody therapeutics - Arsanis Biosciences

Alternative Names: ASN 200; ASN 300; ASN 400

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Arsanis Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Escherichia coli infections; Klebsiella infections
  • Research Bacterial infections; Streptococcal infections
  • No development reported Nosocomial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nosocomial-infections in Austria (Parenteral)
  • 01 Sep 2013 Preclinical trials in Escherichia coli infections (nosocomial) in Austria (Parenteral)
  • 01 Sep 2013 Early research in Bacterial infections (undisclosed non-nosocomial) in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top